Literature DB >> 24674940

The use of a gas chromatograph coupled to a metal oxide sensor for rapid assessment of stool samples from irritable bowel syndrome and inflammatory bowel disease patients.

S F Shepherd1, N D McGuire, B P J de Lacy Costello, R J Ewen, D H Jayasena, K Vaughan, I Ahmed, C S Probert, N M Ratcliffe.   

Abstract

There is much clinical interest in the development of a low-cost and reliable test for diagnosing inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS), two very distinct diseases that can present with similar symptoms. The assessment of stool samples for the diagnosis of gastro-intestinal diseases is in principle an ideal non-invasive testing method. This paper presents an approach to stool analysis using headspace gas chromatography and a single metal oxide sensor coupled to artificial neural network software. Currently, the system is able to distinguish samples from patients with IBS from patients with IBD with a sensitivity and specificity of 76% and 88% respectively, with an overall mean predictive accuracy of 76%.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24674940      PMCID: PMC4871257          DOI: 10.1088/1752-7155/8/2/026001

Source DB:  PubMed          Journal:  J Breath Res        ISSN: 1752-7155            Impact factor:   3.262


  28 in total

Review 1.  AGA technical review on irritable bowel syndrome.

Authors:  Douglas A Drossman; Michael Camilleri; Emeran A Mayer; William E Whitehead
Journal:  Gastroenterology       Date:  2002-12       Impact factor: 22.682

2.  Diagnostic accuracy of point-of-care fecal calprotectin and immunochemical occult blood tests for diagnosis of organic bowel disease in primary care: the Cost-Effectiveness of a Decision Rule for Abdominal Complaints in Primary Care (CEDAR) study.

Authors:  Liselotte Kok; Sjoerd G Elias; Ben J M Witteman; Jelle G Goedhard; Jean W M Muris; Karel G M Moons; Niek J de Wit
Journal:  Clin Chem       Date:  2012-03-09       Impact factor: 8.327

3.  World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010.

Authors:  Charles N Bernstein; Michael Fried; J H Krabshuis; Henry Cohen; R Eliakim; Suleiman Fedail; Richard Gearry; K L Goh; Saheed Hamid; Aamir Ghafor Khan; A W LeMair; Qin Ouyang; J F Rey; Ajit Sood; Flavio Steinwurz; Ole O Thomsen; Alan Thomson; Gillian Watermeyer
Journal:  Inflamm Bowel Dis       Date:  2010-01       Impact factor: 5.325

Review 4.  Genetics and pathogenesis of inflammatory bowel disease.

Authors:  Bernard Khor; Agnès Gardet; Ramnik J Xavier
Journal:  Nature       Date:  2011-06-15       Impact factor: 49.962

5.  Exhaled volatile organic compounds identify patients with colorectal cancer.

Authors:  D F Altomare; M Di Lena; F Porcelli; L Trizio; E Travaglio; M Tutino; S Dragonieri; V Memeo; G de Gennaro
Journal:  Br J Surg       Date:  2013-01       Impact factor: 6.939

6.  Clinical utility of calprotectin and lactoferrin as markers of inflammation in patients with inflammatory bowel disease.

Authors:  Roberta Caccaro; Renata D'Incá; Giacomo Carlo Sturniolo
Journal:  Expert Rev Clin Immunol       Date:  2010-07       Impact factor: 4.473

7.  Volatile organic compounds from feces and their potential for diagnosis of gastrointestinal disease.

Authors:  Catherine E Garner; Stephen Smith; Ben de Lacy Costello; Paul White; Robert Spencer; Chris S J Probert; Norman M Ratcliffe
Journal:  FASEB J       Date:  2007-02-21       Impact factor: 5.191

8.  Analysis of volatile organic compounds of bacterial origin in chronic gastrointestinal diseases.

Authors:  Christopher Walton; Dawn P Fowler; Claire Turner; Wenjing Jia; Rebekah N Whitehead; Lesley Griffiths; Claire Dawson; Rosemary H Waring; David B Ramsden; Jeffrey A Cole; Michael Cauchi; Conrad Bessant; John O Hunter
Journal:  Inflamm Bowel Dis       Date:  2013-09       Impact factor: 5.325

Review 9.  Challenges of cancer biomarker profiling.

Authors:  Karim Bensalah; Francesco Montorsi; Shahrokh F Shariat
Journal:  Eur Urol       Date:  2007-10-01       Impact factor: 20.096

Review 10.  Negative interactions with the microbiota: IBD.

Authors:  Nita H Salzman; Charles L Bevins
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

View more
  8 in total

Review 1.  Diagnosing gastrointestinal illnesses using fecal headspace volatile organic compounds.

Authors:  Daniel K Chan; Cadman L Leggett; Kenneth K Wang
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

2.  The use of a gas chromatography-sensor system combined with advanced statistical methods, towards the diagnosis of urological malignancies.

Authors:  Raphael B M Aggio; Ben de Lacy Costello; Paul White; Tanzeela Khalid; Norman M Ratcliffe; Raj Persad; Chris S J Probert
Journal:  J Breath Res       Date:  2016-02-11       Impact factor: 3.262

3.  A cerumenolomic approach to bovine trypanosomosis diagnosis.

Authors:  João Marcos G Barbosa; Débora Ribeiro de Mendonça; Lurian C David; Taynara C E Silva; Danielly A Fortuna Lima; Anselmo E de Oliveira; Welber Daniel Zanetti Lopes; Maria Clorinda S Fioravanti; Paulo H Jorge da Cunha; Nelson R Antoniosi Filho
Journal:  Metabolomics       Date:  2022-06-23       Impact factor: 4.747

Review 4.  Application of Electronic-Nose Technologies and VOC-Biomarkers for the Noninvasive Early Diagnosis of Gastrointestinal Diseases .

Authors:  Alphus Dan Wilson
Journal:  Sensors (Basel)       Date:  2018-08-09       Impact factor: 3.576

5.  Nonhuman primate breath volatile organic compounds associate with developmental programming and cardio-metabolic status.

Authors:  Andrew C Bishop; Mark Libardoni; Ahsan Choudary; Biswapriya Misra; Kenneth Lange; John Bernal; Mark Nijland; Cun Li; Michael Olivier; Peter W Nathanielsz; Laura A Cox
Journal:  J Breath Res       Date:  2018-05-14       Impact factor: 3.262

6.  Faecal volatile biomarkers of Clostridium difficile infection.

Authors:  Mitesh Patel; Dawn Fowler; Jeremy Sizer; Christopher Walton
Journal:  PLoS One       Date:  2019-04-15       Impact factor: 3.240

7.  Volatile organic compound profiling as a potential biomarker in irritable bowel syndrome: A feasibility study.

Authors:  Kathleen Van Malderen; Nikita Hanning; Helen Lambrechts; Tine Haverhals; Silke Van Marcke; Hannah Ceuleers; Joris G De Man; Benedicte Y De Winter; Kevin Lamote; Heiko U De Schepper
Journal:  Front Med (Lausanne)       Date:  2022-08-04

Review 8.  Are Volatile Organic Compounds Accurate Markers in the Assessment of Colorectal Cancer and Inflammatory Bowel Diseases? A Review.

Authors:  Filippo Vernia; Marco Valvano; Stefano Fabiani; Gianpiero Stefanelli; Salvatore Longo; Angelo Viscido; Giovanni Latella
Journal:  Cancers (Basel)       Date:  2021-05-13       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.